Organon Considering Partnership For Hormone Therapy Livial In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Organon is considering finding a partner to support the introduction of its hormone therapy Livial (tibolone) in the U.S
You may also be interested in...
FDA Rejects Organon’s Livial For Menopause
Akzo Nobel healthcare group Organon plans to continue ongoing trials of tibolone for other indications.
FDA Rejects Organon’s Livial For Menopause
Akzo Nobel healthcare group Organon plans to continue ongoing trials of tibolone for other indications.
Organon, Pfizer Hope Hot Flashes Will Be Hot Market
Organon's 5HT2-antagonist Org 50018 is in Phase II/III development as an alternative to hormone therapy for treatment of hot flashes. Pfizer also has eyes on the market, licensing a University of Rochester patent that covers use of Lyrica.